by | May 25, 2024 | Publications
J Clin Med. 2024 May 8;13(10):2771. doi: 10.3390/jcm13102771. ABSTRACT Background: Multiple myeloma (MM) accounts for about 10-15% of all diagnosed hematologic malignancies and about 1-2% of all cancer cases. Approximately 80-90% of MM patients develop bone disease...
by | May 25, 2024 | Publications
J Clin Med. 2024 May 11;13(10):2829. doi: 10.3390/jcm13102829. ABSTRACT Background: Multiple myeloma (MM) is associated with high morbidity and mortality, with elevated rates of arterial thrombosis and venous thromboembolism (VTE) and ischemic stroke (IS). We aimed to...
by | May 25, 2024 | Publications
Vaccines (Basel). 2024 May 9;12(5):518. doi: 10.3390/vaccines12050518. ABSTRACT Patients with multiple myeloma (MM) are a heterogenous, immunocompromised group with increased risk for COVID-19 morbidity and mortality but impaired responses to primary mRNA SARS-CoV-2...
by | May 25, 2024 | Publications
Jpn J Clin Oncol. 2024 May 24:hyae068. doi: 10.1093/jjco/hyae068. Online ahead of print. ABSTRACT BACKGROUND: Despite advances, most patients with multiple myeloma (MM) experience relapse and repeat multiple treatment lines, highlighting an unmet need for patients...
by | May 25, 2024 | Publications
Z Evid Fortbild Qual Gesundhwes. 2024 May 23:S1865-9217(24)00081-3. doi: 10.1016/j.zefq.2024.04.002. Online ahead of print. ABSTRACT OBJECTIVE: As part of a quality improvement initiative in the context of value-based health care we aimed to optimize the shared...
by | May 24, 2024 | Publications
Curr Oncol. 2024 May 9;31(5):2670-2678. doi: 10.3390/curroncol31050202. ABSTRACT This case report describes the development of Progressive Multifocal Leukoencephalopathy (PML) in a 72-year-old male with relapsed/refractory multiple myeloma (RRMM), following a single...
